On June 17, 2022, the Board of Directors of Statera Biopharma, Inc. (the Company) ratified the appointments of Dr. Uday Saxena and Dr. Blake Hawley as a directors of the Company, to fill the vacancies created by Mr. Saluck and Ms. Verny resignations. Dr. Saxena and Dr. Hawley will serve in such position until the earlier of their deaths, resignations or removal from office. Dr. Saxena and Dr. Hawley will serve as members of the Board's audit committee, compensation committee, and nominating and corporate governance committee.

The Board has affirmatively determined that Dr. Saxena and Dr. Hawley are independent within the meaning of the listing standards of The Nasdaq Stock Market (Nasdaq). In addition, Dr. Saxena and Dr. Hawley are independent under Nasdaq's heightened independence standards applicable to audit committee and compensation committee members. Dr. Saxena is currently a Co-Founder of start-up biotech company, ReaGene Innovations.

Dr. Saxena has 30 plus years of leadership experience in drug discovery research. He has held executive and leadership positions at Parke-Davis (now Pfizer), AtheroGenics, Dr. Reddy's Laboratories and Kareus Therapeutics. During his tenure at Parke-Davis/Pfizer, Dr. Saxena was associated with the team that discovered Lipitor®.

Dr. Saxena has a Ph.D. in Biochemistry from Memorial University and Post-doctoral training at Columbia University. The Company confirms that (1) there is no family relationship between Dr. Saxena and any director or executive officer of the Company, there was no arrangement or understanding between Dr. Saxena. and any other person pursuant to which he was elected to his position with the Company, and there is no transaction between Dr. Saxena and the Company that would require disclosure under Item 404(a) of Regulation S-K. Dr. Hawley is the Founder of Cleopatra Life Inc., Motega Health, Inc., Cedoga Consulting LLC and SBH Nutrition Science LLC.

Dr. Hawley brings an entrepreneurial mindset with a track record of execution. Previously Dr. Hawley served as Chief Commercial Officer of Kindred Biosciences and Managing Director of the United Kingdom and Ireland for Hill's Pet Nutrition, a division of Colgate-Palmolive. His experience includes ten years of profit and loss responsibilities in multiple geographies, with consistent double-digit annual revenue growth in each of the ten years.

He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley holds an M.B.A. from the University of Kansas and a D.V.M. from North Carolina State University.